Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.44 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
| ▸ | PNLIP | P16233 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330768 | 0.88 | EPHX2 (0.52) | MAPK8EPHX2HSD11B1HSD11B2 | |
| SCHEMBL3328670 | 0.81 | HSD11B1 (0.51) | MAPK8EPHX2HSD11B1 | |
| SCHEMBL3329136 | 0.81 | HSD11B1 (0.40) | HSD11B1PNLIPMRGPRX4FFAR1 | |
| SCHEMBL3274695 | 0.76 | HPGD (0.52) | EPHX2 | |
| SCHEMBL13431297 | 0.75 | MAPK8 (0.49) | MAPK8EPHX2HSD11B1 | |
| SCHEMBL13431304 | 0.75 | MAPK8 (0.51) | MAPK8EPHX2HSD11B1 | |
| SCHEMBL13431298 | 0.75 | MAPK8 (0.51) | MAPK8EPHX2HSD11B1 | |
| SCHEMBL16530082 | 0.73 | HSD11B1 (0.57) | MAPK8EPHX2HSD11B1 | |
| SCHEMBL1675970 | 0.73 | HSD11B1 (0.57) | MAPK8EPHX2HSD11B1 | |
| SCHEMBL13383854 | 0.73 | HSD11B1 (0.45) | MAPK8HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | claimed |
| EP-2152081-A1 | NOVEL COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008127924-A1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-10-23 | — | — | WO | claimed |
| EP-2152081-B1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2152081-B1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| US-20100137377-A1 | NOVEL COMPOUNDS | SOREN EBDRUP ET AL | 2010-06-03 | — | — | US | disclosed |
| EP-2152081-A1 | NOVEL COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008127924-A1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127924-A1 | NOVEL COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137377-A1 | NOVEL COMPOUNDS | HSD11B1, CYP11B1, HSD11B2 | MAPK8 2760/4885EPHX2 2422/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.